Treatment of Recalcitrant Medial and Lateral Epicondylitis with Autologous Platelet Rich Plasma; Preliminary Report.
- Author:
Jong Ha LEE
1
;
Jun O YOON
;
Bong Seong JEONG
;
Ho Youn PARK
Author Information
1. Department of Orthopedic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. joonoyoon@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Elbow;
Recalcitrant medial and lateral epicondylitis;
Platelet rich plasma
- MeSH:
Blood Platelets;
Elbow;
Follow-Up Studies;
Humans;
Platelet-Rich Plasma
- From:Journal of the Korean Society for Surgery of the Hand
2010;15(2):71-76
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We evaluated the clinical outcomes of the autologous platelet rich plasma injection for the treatment of recalcitrant medial and lateral epicondylitis. MATERIALS AND METHODS: Nineteen cases with recalcitrant medial and lateral epicondylitis despite of conservative treatment for 1 year were enrolled in this study. Each patient underwent autologous platelet rich plasma injection and followed up minimally of 40 weeks. The assessment included a preoperative and postoperative Visual Analogue Scale (VAS) (0~10) at 4, 8, 12, 24 and 36 weeks and overall satisfaction was evaluated with Roles & Maudsley score at 36 weeks after injection. We also compared the clinical outcomes between medial and lateral epicondylitis group. RESULTS: Mean preoperative VAS was 8.7 points and improved to 5.1, 5.2 and 4.7 at 12, 24 and 36 weeks follow up, respectively. Roles & Maudsley score was excellent in 5 cases(26%), good in 7 cases(37%), acceptable in 4 cases(21%) and poor in 3 cases(16%). On the comparison of medial and lateral epicondylitis group, there was no statistical significant difference (p=0.38). CONCLUSION: The autologous platelet rich plasma injection for recalcitrant medial & lateral epicondylitis is thought to be a alternative treatment option.
